Literature DB >> 3484675

Augmentation of NK activity and/or macrophage-mediated cytotoxicity in the liver by biological response modifiers including human recombinant interleukin 2.

S R Zhang, R R Salup, P E Urias, T A Twilley, J E Talmadge, R B Herberman, R H Wiltrout.   

Abstract

Administration of several biological response modifiers (BRMs) to mice strongly augmented natural killer (NK) activity of leukocytes isolated from the liver. This augmentation of NK activity was induced by two synthetic molecules (MVE-2 and poly ICLC), by two BRMs of bacterial origin (formalin-fixed Propionibacterium acnes: P. acnes and a streptococcal cell wall preparation designated OK-432), as well as a single injection of human recombinant interleukin-2 (hrIL 2). All of these BRMs augmented NK activity in the liver to a greater degree than in the spleen. In addition, adherent leukocytes (greater than 90% macrophages) isolated from the liver following P. acnes administration also exhibited augmented macrophage-mediated cytotoxicity. This cytotoxicity was characterized as macrophage mediated and distinguished from NK activity, on the basis of adherence purification, kinetics of cytotoxicity, and target cell selectivity. The results demonstrate that a variety of BRMs induce augmented natural immunity in the liver and suggest that such organ-associated immune responses may play an important role in the antimetastatic effects of BRMs.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3484675     DOI: 10.1007/BF00199372

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  42 in total

1.  Murine NK cell cultures: effects of interleukin-2 and interferon on cell growth and cytotoxic reactivity.

Authors:  K Kuribayashi; S Gillis; D E Kern; C S Henney
Journal:  J Immunol       Date:  1981-06       Impact factor: 5.422

2.  Measurement of macrophage-mediated cytotoxicity against adherent and non-adherent target cells by release of 11 indium-oxine.

Authors:  R H Wiltrout; D Taramelli; H T Holden
Journal:  J Immunol Methods       Date:  1981       Impact factor: 2.303

3.  In vivo effect of anti-asialo GM1 antibody on natural killer activity.

Authors:  M Kasai; T Yoneda; S Habu; Y Maruyama; K Okumura; T Tokunaga
Journal:  Nature       Date:  1981-05-28       Impact factor: 49.962

4.  In situ activation of murine macrophages by liposomes containing lymphokines.

Authors:  W E Fogler; A Raz; I J Fidler
Journal:  Cell Immunol       Date:  1980-07-15       Impact factor: 4.868

5.  Expression of metastatic potential of allogenic and xenogeneic neoplasms in young nude mice.

Authors:  N Hanna; I J Fidler
Journal:  Cancer Res       Date:  1981-02       Impact factor: 12.701

6.  Role of NK cells in the control of metastatic spread and growth of tumor cells in mice.

Authors:  E Gorelik; R H Wiltrout; K Okumura; S Habu; R B Herberman
Journal:  Int J Cancer       Date:  1982-07-15       Impact factor: 7.396

7.  Selective depletion of NK cell activity in vivo and its effect on the growth of NK-sensitive and NK-resistant tumor cell variants.

Authors:  I Kawase; D L Urdal; C G Brooks; C S Henney
Journal:  Int J Cancer       Date:  1982-05-15       Impact factor: 7.396

8.  Interleukin 2 dependence of human natural killer (NK) cell activity.

Authors:  W Domzig; B M Stadler; R B Herberman
Journal:  J Immunol       Date:  1983-04       Impact factor: 5.422

9.  Variation in selectivity of tumor cell cytolysis by murine macrophages, macrophage-like cell lines and NK cells.

Authors:  R H Wiltrout; M J Brunda; H T Holden
Journal:  Int J Cancer       Date:  1982-09-15       Impact factor: 7.396

10.  Effect of pyran copolymer on activation of murine macrophages: evidence for incomplete activation by use of functional markers.

Authors:  D O Adams; W J Johnson; P A Marino; J H Dean
Journal:  Cancer Res       Date:  1983-08       Impact factor: 12.701

View more
  6 in total

1.  Complete remission of liver metastases from colorectal cancer by treatment with a hepatic artery infusion (HAI) of interleukin-2-based immunochemotherapy: reports of three cases.

Authors:  K Okuno; H Ohnishi; I Nakajima; Y Akabane; K Kurooka; K Koh; K Shindo; M Yasutomi
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

2.  Development of donor cell leukemia following peripheral blood stem cell transplantation for severe aplastic anemia: A case report.

Authors:  Hongbing Ma; Ting Liu
Journal:  Oncol Lett       Date:  2016-04-18       Impact factor: 2.967

Review 3.  Antitumor immunity produced by the liver Kupffer cells, NK cells, NKT cells, and CD8 CD122 T cells.

Authors:  Shuhji Seki; Hiroyuki Nakashima; Masahiro Nakashima; Manabu Kinoshita
Journal:  Clin Dev Immunol       Date:  2011-11-29

4.  Suppression of monocyte and neutrophil function by recombinant IL-2.

Authors:  S E Smith; G D Warren; Y H Thong; J G McCormack
Journal:  Mediators Inflamm       Date:  1993       Impact factor: 4.711

5.  Immunotherapy with low-dose recombinant interleukin 2 after high-dose chemotherapy and autologous stem cell transplantation in neuroblastoma.

Authors:  A Pession; A Prete; F Locatelli; S Pierinelli; A L Pession; R Maccario; E Magrini; B De Bernardi; P Paolucci; G Paolucci
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

Review 6.  Biology of natural killer cells.

Authors:  G Trinchieri
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.